Revenue grew 2% to $503.9m, driven by acquisitions and pharmacy performance, while operating profit declined due to labour and margin pressures. The group expanded its medical network, invested in technology, and maintained strong loyalty programme growth.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.